TEWKSBURY, Mass., September 8, 2021 (Newswire.com) - Otsuka Group Companies (parent company of Cambridge Isotope Laboratories, Inc.) began to celebrate its 100th anniversary on Sept. 1, 2021. Under ...
Otsuka is facing plenty of bleeding, now that its blockbuster antipsychotic Abilify has generic competition. But the company is working hard to soften the blow, and a brand-new FDA approval for an ...
On November 2, 2026, the stock price of Otsuka Corporation (4768) experienced a significant drop, falling by over 12% at one ...
Otsuka Pharmaceutical plans to buy Jnana Therapeutics for $800 million in cash, gaining access to the privately held biotech’s drug discovery platform and an experimental medicine that’s already ...
PRINCETON, N.J. & TOKYO--(BUSINESS WIRE)--Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announce the filing of a New Drug Application ...
Otsuka America, a subsidiary of the Japanese drug and device maker, this month launched a new company focused on digital health. The firm, called Otsuka Precision Health, will roll out its first ...
The company expects full-year 2026 profit attributable to owners of the parent to increase 0.9% year over year to 64.90 billion yen, with basic earnings per share of 171.15 yen. Otsuka closed trading ...
This article has been updated with comments from Proteus and Otsuka. Once valued at $1.5 billion, Proteus Digital Health may now sell to its largest shareholder for $15 million in cash. A Delaware ...
Otsuka and partner Proteus Digital Health envisioned a new version of the antipsychotic Abilify that could track patients and their doses. But the FDA was underwhelmed by the partners' ...
Over the last year, digital has transformed the caregiver experience, but pharma has also been undergoing a metamorphosis in order to reach patients. During the pandemic, life science companies were ...
SAN FRANCISCO--(BUSINESS WIRE)--Otsuka America Pharmaceutical, Inc., (Otsuka) and Lundbeck US (Lundbeck) today presented positive efficacy and safety data from multiple Phase 3 studies of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results